Journal
FUTURE ONCOLOGY
Volume 11, Issue 3, Pages 449-465Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/fon.14.261
Keywords
adverse event management; Child-Pugh B; dose modification; elderly; hepatocellular carcinoma; mRECIST; postprogression treatment; real-world data; response assessment; sorafenib
Categories
Funding
- Bayer HealthCare Pharmaceuticals
- BMS
- Bracco
- Syrtex
- Bayer
- Novartis
- Roche
- Merck Serono
- Gilead Science
- Tibotec
- Vertex
- Merck
- Janssen
- Sanofi
- Bayer SpA
Ask authors/readers for more resources
Understanding the best use of sorafenib is essential in order to maximize clinical benefit in hepatocellular carcinoma. Based on Phase III and noninterventional study data, as well as our extensive experience, we discuss dose modification in order to manage adverse events, disease response evaluation and how to maximize treatment benefit. Sorafenib should be initiated at the approved dose (400 mg twice daily) and reduced/interrupted as appropriate in order to manage adverse events. Dose modification should be considered before discontinuation. Appropriate tumor response assessment is critical. Focusing on radiologic response may result in premature sorafenib discontinuation; symptomatic progression should also be considered. If second-line therapies or trials are unavailable, continuing sorafenib beyond radiologic progression may provide a clinical benefit. Our recommendations enable the maximization of treatment duration, and hence clinical benefit, for patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available